Daxor
  • About Daxor
    • Company Overview
    • Executive Team
    • Board of Directors
    • Careers
    • Contact Us
  • The BVA-100
    • Importance Of Blood Volume Measurement
    • Blood Volume Measurement Test
    • Principle Of Blood Volume Measurement
    • Performing Blood Volume Measurement
    • Blood Volume Measurement Report
    • Resources
    • FAQ’s
  • Healthcare Professionals
    • COVID-19
    • Heart Failure
    • Critical Care
    • Other Indications
    • Clinical Evidence
    • Case Studies
    • The BVA Brief Newsletter
    • Reimbursement
    • Technical Resources
    • Clinical Support Team
  • Innovations
  • Investors
    • Tear Sheet
    • Press Releases
    • Executive Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • SEC Filings
    • FAQ’s
    • Key Contacts
  • Contact
  • About Daxor
    • Company Overview
    • Executive Team
    • Board of Directors
    • Careers
    • Contact Us
  • The BVA-100
    • Importance Of Blood Volume Measurement
    • Blood Volume Measurement Test
    • Principle Of Blood Volume Measurement
    • Performing Blood Volume Measurement
    • Blood Volume Measurement Report
    • Resources
    • FAQ’s
  • Healthcare Professionals
    • COVID-19
    • Heart Failure
    • Critical Care
    • Other Indications
    • Clinical Evidence
    • Case Studies
    • The BVA Brief Newsletter
    • Reimbursement
    • Technical Resources
    • Clinical Support Team
  • Innovations
  • Investors
    • Tear Sheet
    • Press Releases
    • Executive Team
    • Board of Directors
    • Board Committees
    • Governance Documents
    • SEC Filings
    • FAQ’s
    • Key Contacts
  • Contact
News
12 May 2022

Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

admin
News
02 May 2022

New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device

admin
News
06 Apr 2022

New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure

admin
News
23 Mar 2022

Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

admin
News
01 Mar 2022

Daxor Corporation CEO & President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

admin
News
01 Mar 2022

Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021

admin
News
17 Feb 2022

Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

admin
News
02 Feb 2022

Daxor Corporation Commences Trading on The NASDAQ Capital Market

admin
News
21 Jan 2022

Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors

admin
News
20 Jan 2022

Daxor Corporation to Commence Trading on The Nasdaq Capital Market

admin
Previous